TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04027738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRP
Description: The patients received a single 3-ml injection of PRP. Approximately 10-mL of venous blood was drawn from each patient and centrifuged using an Arthrex autologous conditioned plasma (ACP) kit (a low-leukocyte ACP system), spun at a speed of 1500 rpm for 5 minutes. The platelet concentration obtained was approximately 2-3 times greater than the baseline platelet concentration.
Study: NCT03317171

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flavonoids, DHA, EPA
Description: oral administration

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo compound
Description: oral administration
Study: NCT02871739

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Webinar
Description: 1 hour online, interactive webinar that covers shared decision making skills in clinical encounters.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Webinar
Description: 1 hour online, interactive webinar that covers shared decision making skills in clinical encounters.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DA viewing
Description: Participants will receive 3 decisions aids to review.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DA viewing
Description: Participants will receive 3 decisions aids to review.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPI feedback
Description: Rating of shared decision making skills and opportunities for improvement based on transcript of a standardized patient interaction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPI feedback
Description: Rating of shared decision making skills and opportunities for improvement based on transcript of a standardized patient interaction
Study: NCT04721483

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ramicotomy
Description: We will selectively lesion the gray rami communicantes from T3 and T4 thoracic sympathetic ganglia
Study: NCT02307006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline
Description: Surgical prophylaxis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin / Vancomycin
Description: Standard of care surgical prophylaxis
Study: NCT04721483

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ramicotomy
Description: We will selectively lesion the gray rami communicantes from T3 and T4 thoracic sympathetic ganglia
Study: NCT03583424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo hematopoietic cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT00072670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Trabectedin will be administered intravenously as either 0.58 milligram per square meter (mg/m\^2) weekly as 3-hour infusion or 1.5 mg/m\^2 or 1.2 mg/m\^2 every three weeks as 24-hour infusion until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Trabectedin will be administered intravenously as either 0.58 milligram per square meter (mg/m\^2) weekly as 3-hour infusion or 1.5 mg/m\^2 or 1.2 mg/m\^2 every three weeks as 24-hour infusion until disease progression or unacceptable toxicity.
Study: NCT02086942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Induction therapy：1.6mg/m2 or 1.3mg/m2 SC,Days 1, 6, 11, 16 of each 28 day cycles,4 cycle Intensive therapy：1.6mg/m2 or 1.3mg/m2 SC,Days 1, 6, 11, 16 of each 28 day cycles,5 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Induction therapy：1.6mg/m2 or 1.3mg/m2 SC,Days 1, 6, 11, 16 of each 28 day cycles,4 cycle Intensive therapy：1.6mg/m2 or 1.3mg/m2 SC,Days 1, 6, 11, 16 of each 28 day cycles,5 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Induction therapy：300mg/m2 VD Days 1-3 of each 28 day cycles,4 cycles. Intensive therapy：300mg/m2 VD Days 1-3 of each 28 day cycles,5 cycles. Maintenance treatment with CP: 200mg PO Days 1-14 of each 28 day cycles,12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Induction therapy：300mg/m2 VD Days 1-3 of each 28 day cycles,4 cycles. Intensive therapy：300mg/m2 VD Days 1-3 of each 28 day cycles,5 cycles. Maintenance treatment with CP: 200mg PO Days 1-14 of each 28 day cycles,12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Induction therapy：40 mg/d VD Days 1,6,11,16 of each 28 day cycles,4 cycles Intensive therapy：40 mg/d VD Days 1,6,11,16 of each 28 day cycles,5 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Induction therapy：40 mg/d VD Days 1,6,11,16 of each 28 day cycles,4 cycles Intensive therapy：40 mg/d VD Days 1,6,11,16 of each 28 day cycles,5 cycles.
Study: NCT01845285

Intervention type: DEVICE
Intervention: Aortic Valve Replacement
Description: Transthoracic Echo (TTE),CT Scan (ECG triggered, contrast enhanced),Aorto-Iliac Angiogram,Peripheral Evaluation,Coronary Evaluation,12 lead ECG,Arrhythmia Assessment, New York Heart Association (NYHA) functional status, Modified Rankin Score Assessment (mRS) if symptomatic for stroke, Current Cardiac Medications, Transthoracic echo (TTE)
Study: NCT05723016

Intervention type: OTHER
Intervention: preimplantation genetic test for aneuploidies (PGT-a)
Description: preimplantation genetic test for embryo aneuploidies after IVF

Intervention type: OTHER
Intervention: preimplantation genetic test for aneuploidies (PGT-a)
Description: preimplantation genetic test for embryo aneuploidies after IVF

Intervention type: OTHER
Intervention: preimplantation genetic test for aneuploidies (PGT-a)
Description: preimplantation genetic test for embryo aneuploidies after IVF

Intervention type: OTHER
Intervention: preimplantation genetic test for aneuploidies (PGT-a)
Description: preimplantation genetic test for embryo aneuploidies after IVF

Intervention type: OTHER
Intervention: preimplantation genetic test for aneuploidies (PGT-a)
Description: preimplantation genetic test for embryo aneuploidies after IVF

Intervention type: OTHER
Intervention: preimplantation genetic test for aneuploidies (PGT-a)
Description: preimplantation genetic test for embryo aneuploidies after IVF
Study: NCT01991171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: Kinesiotaping intervention is based upon the use of specific elastic tapes (known as Kinesio Tex Gold) that are applied with a certain amount of tension fixed to the skin of patients with the target muscles in a stretched position. The tapes will be placed over the quadriceps muscle.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Kinesio Taping
Description: Kinesiotaping intervention is based upon the use of specific elastic tapes (known as Kinesio Tex Gold) that are applied with a certain amount of tension fixed to the skin of patients with the target muscles in a stretched position. The tapes will be placed over the quadriceps muscle.
Study: NCT04112017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YVOIRE Y-Solution 360
Description: Hyaluronic acid
Study: NCT01674231

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Grape in the form of freeze-dried whole grape powder
Description: 60g freeze-dried whole grape powder with 296mg polyphenols per day for 4 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Grape powder placebo
Description: 60g control food (matched for calories, low in polyphenols, and indistinguishable from active intervention) per day for 4 weeks.
Study: NCT00736801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol and Salmeterol / Fluticasone
Description: Patients inhale salmeterol for 2 weeks, followed by an inhalation of both salmeterol and fluticasone for 2 weeks.
Study: NCT03530475

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound and doppler
Description: • Ultrasound examination (2D gray scale and color doppler )~1. Confirming the presence of placenta previa 2,To assess the possibility of concomitant placenta accreta (Sonographic findings that have been associated with placenta accreta (1) Loss of normal hypoechoic retroplacental zone (2) Multiple vascular lacunae (irregular vascular spaces) within placenta, (3) Blood vessels or placental tissue bridging uterine-placental margin, myometrial-bladder interface, or crossing uterine serosa1 (4) Retroplacental myometrial thickness of 1 mm (5) Bladder wall interruption (6) Presence of placental bulge (7) Utero-vesical hypervascularity (8) presence of lacunae feeder vessels.~3. Assessment of uterine artery Doppler in different cases of placenta previa.~. Documentation of the operative findings during cesarean section and/or cesarean hysterectomy procedures.~Histopathological examination of the hysterectomy specimens to assess the degree of myometrial invasion.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound and doppler
Description: • Ultrasound examination (2D gray scale and color doppler )~1. Confirming the presence of placenta previa 2,To assess the possibility of concomitant placenta accreta (Sonographic findings that have been associated with placenta accreta (1) Loss of normal hypoechoic retroplacental zone (2) Multiple vascular lacunae (irregular vascular spaces) within placenta, (3) Blood vessels or placental tissue bridging uterine-placental margin, myometrial-bladder interface, or crossing uterine serosa1 (4) Retroplacental myometrial thickness of 1 mm (5) Bladder wall interruption (6) Presence of placental bulge (7) Utero-vesical hypervascularity (8) presence of lacunae feeder vessels.~3. Assessment of uterine artery Doppler in different cases of placenta previa.~. Documentation of the operative findings during cesarean section and/or cesarean hysterectomy procedures.~Histopathological examination of the hysterectomy specimens to assess the degree of myometrial invasion.
Study: NCT02979743

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Occupational therapy
Study: NCT00072670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Trabectedin will be administered intravenously as either 0.58 milligram per square meter (mg/m\^2) weekly as 3-hour infusion or 1.5 mg/m\^2 or 1.2 mg/m\^2 every three weeks as 24-hour infusion until disease progression or unacceptable toxicity.
Study: NCT02979743

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Occupational therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occupational therapy puls acupuncture and massage methods
Study: NCT00470392

Intervention type: DRUG
Group type: OTHER
Intervention: Imiquimod
Description: Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Imiquimod (5% topical cream) was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.

Intervention type: DRUG
Group type: OTHER
Intervention: Clobetasol
Description: Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Clobetasol propionate 0.05% was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
Study: NCT04319354

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Analysis of cfDNA
Description: Analysis of cfDNA through liquid biopsy

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Analysis of cfDNA
Description: Analysis of cfDNA through liquid biopsy

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Analysis of cfDNA
Description: Analysis of cfDNA through liquid biopsy
Study: NCT03630653

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel LN in breast cancer recurrence
Description: Sentinel Lymph-Node (LN) procedure and Axillary LN dissection ; Mastectomy or breast conservative surgery
Study: NCT02186002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-451840 10 mg
Description: ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-451840 50 mg
Description: ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-451840 200 mg
Description: ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-451840 500 mg
Description: ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-451840 1000 mg
Description: ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-451840 (Dose to be determined)
Description: ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01728025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Study: NCT00281203

Intervention type: PROCEDURE
Intervention: blood drawing
Description: blood will be drawn on the entry visit and will starting the intravenous (IV) line on the day of bronchoscopy

Intervention type: PROCEDURE
Intervention: fiberoptic bronchoscopy
Description: A flexible instrument will be passed through the mouth and into the lungs. Portions of the lungs will be washed, by injecting and immediately suctioning out a small amount of fluid. The entire return will be used for research purposes, and no results will be reported to the participant. Bronchoscopy is performed once.
Study: NCT02492529

Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological tests
Description: Scales and tests to evaluate:~* Global cognitive performance~* Handedness~* Memory functions performance~* Gestural praxis functions performance~* Lexical and semantic functions performance~* Executive functions performance~* Memory disorders~* Way of life~* Mood

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological tests
Description: Scales and tests to evaluate:~* Global cognitive performance~* Handedness~* Memory functions performance~* Gestural praxis functions performance~* Lexical and semantic functions performance~* Executive functions performance~* Memory disorders~* Way of life~* Mood

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological tests
Description: Scales and tests to evaluate:~* Global cognitive performance~* Handedness~* Memory functions performance~* Gestural praxis functions performance~* Lexical and semantic functions performance~* Executive functions performance~* Memory disorders~* Way of life~* Mood

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A cranial MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A cranial MRI

Intervention type: OTHER
Group type: OTHER
Intervention: Experimental procedure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental procedure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental procedure
Study: NCT03519568

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 (inoculation vaccine)
Description: EV71 vaccine 0.5ml per dose, Wuhan Biological Products Co., Ltd., Wuhan, Hubei Province, China 10μg HepB 0.5ml per dose, Wuhan Biological Products Co., Ltd., Wuhan, Hubei Province, China 30ug MPSV-A 0.5ml per dose, Wuhan Biological Products Co., Ltd., Wuhan, Hubei Province, China MR 0.5ml per dose, Beijiing Biological Products Co., Ltd., Beijing, China JE-L 0.5ml per dose, Chengdu Biological Products Co., Ltd., Chengdu,Sichuan Province, China

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EV71 (inoculation vaccine)
Description: EV71 vaccine 0.5ml per dose, Wuhan Biological Products Co., Ltd., Wuhan, Hubei Province, China 10μg HepB 0.5ml per dose, Wuhan Biological Products Co., Ltd., Wuhan, Hubei Province, China 30ug MPSV-A 0.5ml per dose, Wuhan Biological Products Co., Ltd., Wuhan, Hubei Province, China MR 0.5ml per dose, Beijiing Biological Products Co., Ltd., Beijing, China JE-L 0.5ml per dose, Chengdu Biological Products Co., Ltd., Chengdu,Sichuan Province, China

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EV71 (inoculation vaccine)
Description: EV71 vaccine 0.5ml per dose, Wuhan Biological Products Co., Ltd., Wuhan, Hubei Province, China 10μg HepB 0.5ml per dose, Wuhan Biological Products Co., Ltd., Wuhan, Hubei Province, China 30ug MPSV-A 0.5ml per dose, Wuhan Biological Products Co., Ltd., Wuhan, Hubei Province, China MR 0.5ml per dose, Beijiing Biological Products Co., Ltd., Beijing, China JE-L 0.5ml per dose, Chengdu Biological Products Co., Ltd., Chengdu,Sichuan Province, China
Study: NCT02052921

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectal resection
Description: Surgical rectal resection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Study: NCT02186002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00624533

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GDS Method (muscular chains physical therapy method)
Description: Experimental group received 15 GDS method sessions based on the equilibration of articular and muscular tensions that reduced trunk and lumbopelvic stability. GDS method combine specific technics of manual therapy, spinal stabilisation and stretching exercises (4 sessions),supervised group exercise therapy (10 sessions) and home exercise programme with individualised exercises (1 session) Experimental group received 2 sessions of 50 minutes per week during 8 weeks.
Study: NCT00624533

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy in Primary Health Care
Description: Conventional Physical Therapy in Spanish Primary Care Units are based on Electrotherapy (TENS and microwave thermotherapy) and a standard written advices. Patients received 14 sessions of 40 minutes of conventional TENS, 10 minutes of microwave thermotherapy and 1 last session of standard written advices.~Conventional Physical Therapy group received 2 sessions of 50 minutes per week during 8 weeks.
Study: NCT00554437

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UW Falls Prevention Program
Description: The intervention model is of a community-based multifactorial intervention that links participants to existing medical care and service networks. The intervention used an algorithm based on the University of Wisconsin Falls Prevention Clinic, designed to identify predisposing factors for falls; induce risk reduction changes in medical conditions, medications, behavior, physical status, and home environment through recommendations to participants and their physicians; and make sure these changes are long-lasting through follow-up and linkages to other care networks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: UW Falls Prevention Program
Description: The intervention model is of a community-based multifactorial intervention that links participants to existing medical care and service networks. The intervention used an algorithm based on the University of Wisconsin Falls Prevention Clinic, designed to identify predisposing factors for falls; induce risk reduction changes in medical conditions, medications, behavior, physical status, and home environment through recommendations to participants and their physicians; and make sure these changes are long-lasting through follow-up and linkages to other care networks.
Study: NCT01845792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel with Abiraterone Acetate
Description: Cabazitaxel intravenously every 3 weeks, in combination with abiraterone acetate and prednisone orally daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabazitaxel
Description: Cabazitaxel intravenously every 3 weeks
Study: NCT01066988

Intervention type: OTHER
Group type: OTHER
Intervention: ORB Ocular Emulsion
Description: lubricant eye drop

Intervention type: OTHER
Group type: OTHER
Intervention: SootheXP Emollient (Lubricant) Eye Drops
Description: lubricant eye drop
Study: NCT02180334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosapride citrate
Description: On the day of MMTT, 1 tablet (5 mg) of mosapride will be administered orally to participants of 'mosapride' arm. After 1 hour, MMTT will be performed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Linagliptin
Description: During run-in period, 1 tablet (5mg) per day will provided for 7 days. On the day of MMTT, 1 tablet (5 mg) of linagliptin will be administered orally to participants of both arms. After 1 hour, MMTT will be performed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: During run-in period, 1 tablet (5mg) per day will provided for 7 days. On the day of MMTT, 1 tablet (5 mg) of linagliptin will be administered orally to participants of both arms. After 1 hour, MMTT will be performed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen (paracetamol)
Description: On the day of MMTT, 3 tablets (1500 mg) of acetaminophen (paracetamol) will be administered orally to participants of both arms at the start of MMTT with manufactured mixed meal (0 min).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen (paracetamol)
Description: On the day of MMTT, 3 tablets (1500 mg) of acetaminophen (paracetamol) will be administered orally to participants of both arms at the start of MMTT with manufactured mixed meal (0 min).
Study: NCT03025828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTHar
Description: for 6 months
Study: NCT01498640

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collagenase clostridium histolyticum
Description: up to three 0.58 mg injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collagenase clostridium histolyticum
Description: up to three 0.58 mg injections
Study: NCT03023085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI4700
Description: BLI4700 bowel preparation